Literature DB >> 3519654

Appearance of multiple benign paraproteins during early engraftment of soy lectin T cell-depleted haploidentical bone marrow cells in severe combined immunodeficiency.

P Ghory, S Schiff, R Buckley.   

Abstract

Recent advances in the prevention of graft-versus-host disease through postthymic T-cell depletion have allowed the use of haploidentical bone marrow cells for immunologic reconstitution of severe combined immunodeficiency disease. We report a male infant with severe combined immunodeficiency (with normal adenosine deaminase) who developed two IgG kappa and one IgA lambda paraproteins 7 weeks following the administration of 1.4 X 10(9) maternal bone marrow cells depleted of postthymic T cells by soy lectin agglutination and sheep erythrocyte rosetting. Serum IgG rose from 128 to 820 mg/dl, and IgA from 0 to 2400 mg/dl, peaking at 10 weeks postgrafting. By 14 weeks posttransplantation T-cell numbers and function had risen to normal (all dividing T cells had the donor karyotype) and paraprotein concentrations began to decline. These observations strongly suggest that the later-appearing T cells regulated the B-cell clones from which the paraproteins were derived. Failure of such function to appear could account for the increased incidence of B-cell lymphomas in severe combined immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519654     DOI: 10.1007/bf00918749

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  38 in total

1.  Immunoglobulins and transient paraproteins in sera of patients with the Wiskott-Aldrich syndrome: a follow-up study.

Authors:  J Radl; L H Dooren; A Morell; F Skvaril; J M Vossen; C H Uittenbogaart
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

2.  Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency.

Authors:  J De Koning; D W Van Bekkum; K A Dicke; L J Dooren; J Rádl; J J Van Rood
Journal:  Lancet       Date:  1969-06-21       Impact factor: 79.321

3.  A paraprotein in severe combined immunodefeciency disease detected by immunoelectrophoretic analysis of plasma.

Authors:  S R De Fazio; B S Criswell; S L Kimzey; M A South; J R Montgomery
Journal:  Clin Exp Immunol       Date:  1975-03       Impact factor: 4.330

4.  Severe combined immunodeficiency with natural killer-cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells.

Authors:  L J Sindel; R H Buckley; S E Schiff; F E Ward; G H Mickey; A T Huang; C Naspitz; H Koren
Journal:  J Allergy Clin Immunol       Date:  1984-06       Impact factor: 10.793

5.  Chronic cytomegalovirus infection, immunodeficiency, and monoclonal gammopathy-antigen-driven malignancy?

Authors:  T Groshong; S Horowitz; J Lovchik; A Davis; R Hong
Journal:  J Pediatr       Date:  1976-02       Impact factor: 4.406

6.  Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.

Authors:  R H Buckley; S E Schiff; H A Sampson; R I Schiff; M L Markert; A P Knutsen; M S Hershfield; A T Huang; G H Mickey; F E Ward
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

7.  Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the immunodeficiency--cancer registry.

Authors:  B D Spector; G S Perry; J H Kersey
Journal:  Clin Immunol Immunopathol       Date:  1978-09

8.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1.

Authors:  B Perussia; S Starr; S Abraham; V Fanning; G Trinchieri
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients.

Authors:  G Frizzera; D W Hanto; K J Gajl-Peczalska; J Rosai; R W McKenna; R K Sibley; K P Holahan; L L Lindquist
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

10.  Natural killing in immunodeficient patients.

Authors:  H S Koren; D B Amos; R H Buckley
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

View more
  7 in total

Review 1.  Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes.

Authors:  Rebecca H Buckley
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

2.  Monoclonal gammopathies in children.

Authors:  E Gerritsen; J Vossen; M van Tol; C Jol-van der Zijde; R Van der Weijden-Ragas; J Radl
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

3.  Do infections induce monoclonal immunoglobulin components?

Authors:  H Haas; S Anders; G W Bornkamm; E Mannweiler; H Schmitz; J Radl; M Schlaak
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

4.  Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency.

Authors:  E F Kent; J Crawford; H J Cohen; R H Buckley
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

5.  Acute monocytic leukemia in a dog with X-linked severe combined immunodeficiency.

Authors:  P J Felsburg; R L Somberg; G S Krakowka
Journal:  Clin Diagn Lab Immunol       Date:  1994-07

6.  X-linked severe combined immunodeficiency (X-SCID) with high blood levels of immunoglobulins and Aspergillus pneumonia successfully treated with micafangin followed by unrelated cord blood stem cell transplantation.

Authors:  Shinichi Kobayashi; Shizuko Murayama; Osamu Tatsuzawa; Goro Koinuma; Kazuteru Kawasaki; Chikako Kiyotani; Masaaki Kumagai
Journal:  Eur J Pediatr       Date:  2006-08-17       Impact factor: 3.860

Review 7.  Advances in the understanding and treatment of human severe combined immunodeficiency.

Authors:  R H Buckley
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.